BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Miyamoto Y, Sakamoto Y, Yoshida N, Baba H. Efficacy of S-1 in colorectal cancer. Expert Opin Pharmacother 2014;15:1761-70. [PMID: 25032886 DOI: 10.1517/14656566.2014.937706] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
Number Citing Articles
1 Winther SB, Zubcevic K, Qvortrup C, Vestermark LW, Jensen HA, Krogh M, Sorbye H, Pfeiffer P; on behalf of the Academy of Geriatric Cancer Research (AgeCare). Experience with S-1 in older Caucasian patients with metastatic colorectal cancer (mCRC): Findings from an observational chart review. Acta Oncologica 2016;55:881-5. [DOI: 10.3109/0284186x.2016.1161825] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
2 Cioffi JH, Estes DJ, Florou V, Ardalan B. Treatment of advanced colorectal cancer in a patient with cardiotoxic reactions to 5-fluorouracil and capecitabine using suboptimal doses. BMJ Case Rep 2017;2017:bcr-2017-220952. [PMID: 29183892 DOI: 10.1136/bcr-2017-220952] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
3 Sun S, Yu H, Wang H, Zhang H, Wu X, Wang J, Chang J. Phase II Study of S-1 plus Cisplatin as First-Line Therapy in Patients with Metastatic Esophageal Carcinoma. Oncol Res Treat 2019;42:115-22. [PMID: 30799403 DOI: 10.1159/000495700] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
4 Lin XL, Xiao XY. Progress in neoadjuvant drug therapy of rectal cancer. Shijie Huaren Xiaohua Zazhi 2018; 26(22): 1340-1347 [DOI: 10.11569/wcjd.v26.i22.1340] [Reference Citation Analysis]
5 Cohen DT, Zhang C, Fadzen CM, Mijalis AJ, Hie L, Johnson KD, Shriver Z, Plante O, Miller SJ, Buchwald SL, Pentelute BL. A chemoselective strategy for late-stage functionalization of complex small molecules with polypeptides and proteins. Nat Chem 2019;11:78-85. [PMID: 30397320 DOI: 10.1038/s41557-018-0154-0] [Cited by in Crossref: 46] [Cited by in F6Publishing: 29] [Article Influence: 11.5] [Reference Citation Analysis]
6 Li Z, Mao W, Lin N, Han S. Concurrent radiotherapy with S-1 plus cisplatin versus concurrent radiotherapy with cisplatin alone for the treatment of locally advanced cervical carcinoma: a pilot randomised controlled trial. Clin Transl Oncol 2016;18:413-7. [PMID: 26304854 DOI: 10.1007/s12094-015-1385-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
7 Miyamoto Y, Tsuji A, Tanioka H, Maekawa S, Kawanaka H, Kitazono M, Oki E, Emi Y, Murakami H, Ogata Y, Saeki H, Shimokawa M, Natsugoe S, Akagi Y, Baba H, Maehara Y. S-1 and irinotecan plus bevacizumab as second-line chemotherapy for patients with oxaliplatin-refractory metastatic colorectal cancer: a multicenter phase II study in Japan (KSCC1102). Int J Clin Oncol 2016;21:705-12. [DOI: 10.1007/s10147-015-0943-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
8 Delhorme J, Bersuder E, Terciolo C, Vlami O, Chenard M, Martin E, Rohr S, Brigand C, Duluc I, Freund J, Gross I. CDX2 controls genes involved in the metabolism of 5-fluorouracil and is associated with reduced efficacy of chemotherapy in colorectal cancer. Biomedicine & Pharmacotherapy 2022;147:112630. [DOI: 10.1016/j.biopha.2022.112630] [Reference Citation Analysis]
9 Vodenkova S, Buchler T, Cervena K, Veskrnova V, Vodicka P, Vymetalkova V. 5-fluorouracil and other fluoropyrimidines in colorectal cancer: Past, present and future. Pharmacol Ther 2020;206:107447. [PMID: 31756363 DOI: 10.1016/j.pharmthera.2019.107447] [Cited by in Crossref: 73] [Cited by in F6Publishing: 74] [Article Influence: 24.3] [Reference Citation Analysis]
10 García-Alfonso P, Muñoz Martín AJ, Ortega Morán L, Soto Alsar J, Torres Pérez-Solero G, Blanco Codesido M, Calvo Ferrandiz PA, Grasso Cicala S. Oral drugs in the treatment of metastatic colorectal cancer. Ther Adv Med Oncol 2021;13:17588359211009001. [PMID: 33995592 DOI: 10.1177/17588359211009001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
11 Chionh F, Lau D, Yeung Y, Price T, Tebbutt N. Oral versus intravenous fluoropyrimidines for colorectal cancer. Cochrane Database Syst Rev 2017;7:CD008398. [PMID: 28752564 DOI: 10.1002/14651858.CD008398.pub2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
12 Kusumoto T, Ishiguro M, Nakatani E, Yoshida M, Inoue T, Nakamoto Y, Shiomi A, Takagane A, Sunami E, Shinozaki H, Takii Y, Maeda A, Ojima H, Hashida H, Mukaiya M, Yokoyama T, Nakamura M, Munemoto Y, Sugihara K. Updated 5-year survival and exploratory T x N subset analyses of ACTS-CC trial: a randomised controlled trial of S-1 versus tegafur-uracil/leucovorin as adjuvant chemotherapy for stage III colon cancer. ESMO Open 2018;3:e000428. [PMID: 30425843 DOI: 10.1136/esmoopen-2018-000428] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]